Multinational Analysis of Estimated Health Care Costs Related to Extended-Interval Fixed Dosing of Checkpoint Inhibitors
- 1 February 2023
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 6 (2) , e230490
Abstract
As of January 2021, pembrolizumab has received 39 US Food and Drug Administration (FDA) approvals for the treatment of cancer. Initially approved with weight-based dosing, there was a subsequent movement toward using fixed doses for all patients, first with 200 mg every 3 weeks, and more recently 400 mg every 6 weeks.1 It has previously been argued that the move to fixed dosing from weight-based dosing has maintained efficacy but increased costs.2 While lower doses of immune checkpoint inhibitors have been strongly recommended in other publications,3-5 we recognize that the FDA-approved dose levels and schedules remain the standard of care in many health care settings.Keywords
This publication has 9 references indexed in Scilit:
- AIOM abstracts:Tumori Journal, 2020
- Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial CarcinomaNew England Journal of Medicine, 2020
- Alternative dosing regimens for atezolizumab: right dose, wrong frequencyCancer Chemotherapy and Pharmacology, 2019
- On discount rates for economic evaluations in global healthHealth Policy and Planning, 2019
- Time Is Money: Optimizing the Scheduling of NivolumabJournal of Clinical Oncology, 2018
- A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation.Journal of Clinical Oncology, 2018
- A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non–Small Cell Lung CancerJNCI: Journal of the National Cancer Institute, 2017
- Pembrolizumab as Second-Line Therapy for Advanced Urothelial CarcinomaNew England Journal of Medicine, 2017
- Practical approach for using Medicare data to estimate costs for cost–effectiveness analysisExpert Review of Pharmacoeconomics & Outcomes Research, 2005